Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine and Alvin J. Siteman Cancer Center, St. Louis, MO 63110, USA.
Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2078-84. doi: 10.1158/1055-9965.EPI-11-0605.
Intervention trials in cancer survivors play an important and growing role in complementing the wealth of knowledge obtained from observational studies about how lifestyle can improve clinical, physiologic, and psychological outcomes. As the number of intervention trials grows, attention to study design and reporting is essential to establishing a high-quality data pool from which to make evidence-based recommendations and guidelines. We highlight several key issues important to the design and interpretation of intervention trials in cancer survivors. Intervention dose and duration both matter in trials of cancer survivors, yet few trials have evaluated different intervention doses and few intervention trials with multiyear follow-up exist. Finally, there is a need for interventions both of longer duration and those that take a practical trials approach and reflect clinical practice to speed implementation within practice and improve outcomes for cancer survivors.
在补充观察性研究中获得的关于生活方式如何改善临床、生理和心理结局的大量知识方面，癌症幸存者的干预试验发挥着重要且日益增长的作用。随着干预试验数量的增加，关注研究设计和报告对于建立高质量的数据池以制定基于证据的建议和指南至关重要。我们强调了癌症幸存者干预试验设计和解释中几个重要的关键问题。干预剂量和持续时间在癌症幸存者的试验中都很重要，但很少有试验评估不同的干预剂量，也很少有具有多年随访的干预试验存在。最后，需要进行持续时间更长的干预，以及采用实用试验方法并反映临床实践的干预，以加快在实践中的实施并改善癌症幸存者的结局。
